ACTRIMS: Americas Committee for Treatment and Research in Multiple Sclerosis
Conference Coverage
MRI biomarker to be tested in MS
A new prospective trial aims to prove that central vein sign can distinguish MS from clinical mimics.
Conference Coverage
Ozanimod shows long-term safety, despite a pandemic
Open-label study confirms efficacy and COVID-19–related safety.
Conference Coverage
B-cell therapy for MS may impact COVID-19 vaccination
A prospective study found improved neutralizing antibody response with more time elapsed since therapy and vaccination.
Conference Coverage
Evidence mounts for paramagnetic rim lesions in diagnosing MS
The presence and number of iron rim lesions hold a prognostic value for long-term disability in MS.
Conference Coverage
Spinal cord atrophy predicts ‘silent progression’ in MS
This is a potentially important biomarker for disease progression that may otherwise go unrecognized by clinicians and patients.
Conference Coverage
Can supplementary estrogen relieve MS symptoms in menopausal women?
Research suggests lowered hormone levels may worsen the disease.
Conference Coverage
Sun exposure linked to reduced pediatric MS risk
Children should spend at least 30 minutes outdoors in the sun every day, while using adequate sun protection.
Conference Coverage
Erythropoietin falls short of neuroprotection in optic neuritis
“EPO conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis as a clinically isolated syndrome.”
Conference Coverage
Disease progression and therapy response vary in MS by ethnicity
African Americans and Hispanics had more severe illness than Caucasians, and there were other differences as well.
Conference Coverage
Newly approved drugs offer new hope in NMOSD
Trio of medications offer relief from relapses, neurologist tells colleagues
Conference Coverage
Infections – especially urinary and kidney – are higher in MS
Among patients with MS, the infection rate was more than quadruple the rate in a control cohort.
Conference Coverage
Anti-CD20s linked to higher COVID-19 severity in MS
Older age and disability are also linked to extra risk, registries find, but not other DMTs.
Conference Coverage
Certain DMTs in MS may attenuate COVID-19 vaccines
Adjust timing if feasible, neurologist says, but focus on getting shots in arms.
Conference Coverage
Natalizumab postinfusion reactions rare; is monitoring necessary?
New findings “highlight a potential opportunity to improve and streamline the infusion and post-infusion monitoring process.”
Conference Coverage
NfL levels linked to worse disability in real-world MS
New findings shed light on how best to apply serum filament light chain levels to individual patients.